October 19, 2010

HELIX BIOPHARMA CORP. FILES IND FOR ITS PLANNED PHASE II/III EFFICACY TRIAL OF TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH LOW-GRADE CERVICAL LESIONS (PDF)

AURORA, Ontario, October 19, 2010 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical product candidates for the prevention and treatment of cancer, today announced that it has filed an
investigational new drug (“IND”) application with the United States Food and Drug Administration (“FDA”) seeking approval
to perform its planned Phase II/III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. Topical Interferon Alpha-2b is the Company’s most advanced product in development and incorporates its proprietary Biphasix™ drug delivery technology, designed to offer a superior means of delivering interferon-alpha-2b therapeutically to HPV-infected tissues.